RheoCAR-T™ Platform

A proprietary platform enabling Cell Therapy 3.0

Illustration of a person with a vaccination shot near their arm.

Scalable

Novel T cell targeting to enable safe and efficient in vivo CAR-T engineering with a single dose‍ ‍

A sleek, black race car emitting flames from its exhaust at sunset on a race track.

Powerful

Modular platform for integrating diverse potency-enhancing payloads enabling deep and durable responses

Close-up of a car speedometer showing a speed of 200 km/h with illuminated red and orange warning lights.

Controllable

Tight CAR and payload control with low dose of FDA-approved small molecule

RheoBrick™ ON-switch

Tuning system to enable armoring

Diagram illustrating how lenalidomide affects CAR T-cell therapy in tumor cells. The first two panels show typical CAR signaling suppressed without lenalidomide. The third panel demonstrates lenalidomide promoting CAR signaling, cargo expression, and CAR-T activation, with the drug inducing degradation of inhibitory components.

Proprietary degron functional in vivo at sub clinical doses of lenalidomide

IL-15 armoring

More potent and tunable CAR-Ts

Scientific graph comparing in vitro cytotoxicity assay results of classic CAR-T therapy with RhéoCAR-T therapy, with and without lenalidomide, displaying enhanced activity in presence of lenalidomide, labeled with a large blue arrow pointing downward and a red box note indicating no anti-tumor activity without lenalidomide.
Legend explaining conditions with colored symbols: grey circle for control + vehicle, grey square for control + lenalidomide, blue circle for conv CAR-T + vehicle, blue square for conv CAR-T + lenalidomide, red circle for RheoCAR-T /IL15 + vehicle, red square for RheoCAR-T /IL15 + lenalidomide.

BCMA CAR-T